| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (replaced TA376) |
|
Medicine details |
|
| Medicine name | radium-223 dichloride (Xofigo®) |
| Formulation | 1000 kilobecquerels/ml solution for injection |
| Reference number | 1221 |
| Indication | Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/12/2013 |
| NICE guidance | |